RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance

U.S. Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
30.33-0.28 (-0.90%)
At close: 3:59PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close30.60
Bid0.00 x
Ask0.00 x
Day's Range30.19 - 30.39
52 Week Range25.25 - 33.77
Avg. Volume1,412,829
Market Cap205.8B
PE Ratio (TTM)21.73
Earnings DateN/A
Dividend & Yield1.02 (3.33%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team
    Investor's Business Daily2 hours ago

    Exelixis Rockets On Bristol, Roche I-O Ties Following Merck-Incyte Team

    Exelixis is teaming up with Bristol-Myers Squibb and Roche to test its Cabometyx and their immuno-oncology drugs in liver and bladder cancer.

  • PR Newswire8 hours ago

    New frontiers in cancer research and treatment to be explored by global experts at Tucson Symposium

    TUCSON, Ariz., Feb. 27, 2017 /PRNewswire/ -- More than 500 pathologists, oncologists, scientific researchers and healthcare leaders will converge in Tucson for the 13th annual Tucson Symposium, February 28 to March 1. The two-day conference, which is sponsored by Ventana Medical Systems, Inc., a member of the Roche Group, draws top scientific collaborators from around the globe to hear from leading experts about the latest hypotheses, breakthroughs and innovations in cancer research and treatments. Topics will focus on developments in immunotherapy, genomics, technology, tumor heterogeneity and cancer evolution and personalized healthcare.

  • Investopedia3 days ago

    Novartis Lung Cancer Drug Combo Gets CHMP Nod

    Novartis has secured a positive opinion from European CHMP for its lung cancer drug combo.